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Switching on the lights for gene therapy
Abstract
Strategies for non-invasive and quantitative imaging of gene expression in vivo have been developed
over the past decade. Non-invasive assessment of the dynamics of gene regulation is of interest for the
detection of endogenous disease-specific biological alterations (e.g., signal transduction) and for
monitoring the induction and regulation of therapeutic genes (e.g., gene therapy). To demonstrate that
non-invasive imaging of regulated expression of any type of gene after in vivo transduction by versatile
vectors is feasible, we generated regulatable herpes simplex virus type 1 (HSV-1) amplicon vectors
carrying hormone (mifepristone) or antibiotic (tetracycline) regulated promoters driving the proportional
co-expression of two marker genes. Regulated gene expression was monitored by fluorescence
microscopy in culture and by positron emission tomography (PET) or bioluminescence (BLI) in vivo.
The induction levels evaluated in glioma models varied depending on the dose of inductor. With
fluorescence microscopy and BLI being the tools for assessing gene expression in culture and animal
models, and with PET being the technology for possible application in humans, the generated vectors
may serve to non-invasively monitor the dynamics of any gene of interest which is proportionally
co-expressed with the respective imaging marker gene in research applications aiming towards
translation into clinical application.
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Strategies for non-invasive and quantitative imaging of gene expression in vivo have been developed over the past decade.
Non-invasive assessment of the dynamics of gene regulation is of interest for the detection of endogenous disease-specific
biological alterations (e.g., signal transduction) and for monitoring the induction and regulation of therapeutic genes (e.g.,
gene therapy). To demonstrate that non-invasive imaging of regulated expression of any type of gene after in vivo
transduction by versatile vectors is feasible, we generated regulatable herpes simplex virus type 1 (HSV-1) amplicon vectors
carrying hormone (mifepristone) or antibiotic (tetracycline) regulated promoters driving the proportional co-expression of two
marker genes. Regulated gene expression was monitored by fluorescence microscopy in culture and by positron emission
tomography (PET) or bioluminescence (BLI) in vivo. The induction levels evaluated in glioma models varied depending on the
dose of inductor. With fluorescence microscopy and BLI being the tools for assessing gene expression in culture and animal
models, and with PET being the technology for possible application in humans, the generated vectors may serve to non-
invasively monitor the dynamics of any gene of interest which is proportionally co-expressed with the respective imaging
marker gene in research applications aiming towards translation into clinical application.
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INTRODUCTION
Molecular imaging has become an important technology to non-
invasively assess and monitor disease-specific biological processes
in vivo. It is based on nuclear, magnetic resonance and optical
imaging. In recent years reporter systems for these imaging
techniques have been developed allowing the analysis of dynamic
processes of endogenous and exogenous gene expression in living
animals [1–4].
Moreover, imaging is being used to further develop new gene–
and cell-based therapies [5,6]. To non-invasively assess exogenous
gene expression, e.g., imaging expression of a therapeutic trans-
gene, strategies have been developed to couple and proportionally
co-express a reporter gene with a transgene of interest [7–10]. The
expression of the gene of interest is indirectly localized and
quantified by the assessment of the marker gene. An ideal marker
gene is not endogenously expressed in the host tissue and codes for
an enzyme or receptor. Expression of the marker gene in
transduced cells leads to enzyme-mediated trapping and accumu-
lation of a specific substrate in the cell or by receptor-mediated
specific binding on the cell surface. One of the most commonly
used reporter genes in PET imaging is the HSV-1 thymidine
kinase gene (HSV-1-tk). Saito [11] and Tjuvajev et al. [12] first
described the HSV-1-tk as a suitable reporter gene to follow herpes
virus infection and to image the expression of gene transduction in
vivo.
Expression of reporter genes can be driven by different types of
promoters or enhancer elements to monitor e.g., tissue-specific
gene expression or transcriptional regulation [13]. Reporter
systems bearing a reporter gene under control of endogenous
enhancer elements have been used to monitor transcriptional
regulation of p53-dependent genes [14], albumin gene expression
[15] as well as T-cell activation [16].
Besides these endogenously regulated systems, inducible vector
systems have been developed that allow the regulation of
transduced genes in response to an exogenous compound. Various
types of inducible systems have been established, regulated by e.g.,
antibiotics, hormones, heat shock or heavy metal ions [17–21].
One widely used regulated gene expression system is the
tetracycline-responsive system developed by Gossen and Bujard
[17] that is based on control elements of the tetracycline–resistance
operon of E. coli. In this Tet-On/Off system a tetracycline deriva-
tive (doxycycline) binds to the reverse tetracycline-responsive
transactivator (rtTA) and induces its binding to the Tet-controlled
minimal CMV-promoter and, thus, its activation that leads to
expression of the controlled gene [22]. A modification of this
system uses a bi-directional doxycycline inducible promoter (PBI-1)
controlling the expression of two independent genes [23]. Another
regulatable system is the mifepristone or RU486 inducible system
(‘‘Gene-Switch’’) [24]. The basis is an inducible chimeric tran-
scription factor, consisting of (i) the ligand binding domain (LBD)
of a mutant progesterone receptor that binds the progesterone
antagonist RU 486 (mifepristone); (ii) the DNA binding domain
from the yeast transcription factor Gal4 (GAL4DBD); and (iii) the
activation domain from the HSV-1 protein VP16 or the human
p65 [25]. Both, the Tet- and the Gene Switch system have been
shown to be suitable tools to regulate gene expression in vivo [25–
30] but rarely have been monitored by means of molecular
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imaging. Sun et al. were the first to image gene induction in a
tumor xenograft model in living animals by using ex vivo
transduced stable cell clones expressing the regulator and
regulated genes [31].
Here, we report for the first time on the quantitative dynamics of
regulated gene expression after transduction of co-regulated imag-
ing genes by HSV-1 amplicon vectors containing doxycycline- or
mifepristone -regulated elements [32]. The HSV-1 amplicon
vectors include different reporter genes under control of the
respective regulatory elements. Induced gene expression was
quantified in cell culture (fluorescence microscopy) and in vivo (BLI,
PET). Our universal HSV-1 amplicon vectors allow (i) efficient
transduction of transgenes in vivo; (ii) induction of gene expression;
and (iii) non-invasive assessment of the dynamics of the location and
magnitude of any gene expression co-regulated with the marker
gene in vivo.
RESULTS
Construction of regulated HSV-1 amplicons
expressing the PET-imaging gene HSV-tk39 or
HSV-1-tkgfp17 as well as optical imaging genes
Two different regulated HSV-1 amplicon vectors were constructed
based on the Tet-system (HET6C-tk39) [17,22] and on the
antiprogestin system (HSV-Switch-TG17) [24] (Figure 1A). In
HET6C-tk39, the gene for the specific HSV-1-tk mutant, tk39 [33],
as well as the rfp gene are under control of a bi-directional
tetracycline-responsive promoter (PBI-1). In HSV-Switch-TG17,
the tkgfp17 fusion gene [34] was placed under transcriptional
control of the Gal4 Upstream Activation Sequences (UAS). Thus,
induction of gene expression can be detected in cell culture by
fluorescence microscopy via RFP or eGFP expression and in vivo
by PET via TK expression. For bioluminescence imaging the
HET6C-luc vector was used, where tk39 is substituted by the
luciferase gene (luc). All HSV-1 amplicon vectors contain
transactivator coding sequences and the regulated target genes;
HET6C vectors also contain a tetracycline controlled transcrip-
tional silencer tTS [35] (Figure 1A).
To verify whether expression of viral TK is regulated by the
respective inducer (mifepristone or doxycycline), human Gli36-
DEGFR cells were infected with HET6C-tk39 and HSV-Switch-
TG17, respectively, and protein expression was assessed by
Western Blot. The fusion protein TG17 was expressed only in
cells infected with HSV-Switch-TG17 in the presence of
mifepristone (Figure 1B, lane2). HSV-TG17 (CMV promoter)
infected cells served as positive control (Figure 1B, lane 3).
Likewise, expression of TK39 was only observed in HET6C-tk39
infected cells after addition of doxycycline (Figure 1B, lane 6).
Figure 1. Inducible HSV-amplicon constructs. (A) The doxycycline-regulated HET6C-tk39 vector consists of a bi-directional CMV promoter (BiCMV)
controlling gene expression of the transactivator rtTA and the tetracycline controlled transcriptional silencer tTS [35]. A bi-directional tet-responsive
promoter (PBI-1) controls expression of the marker genes rfp and HSV-1-tk39. In the absence of doxycycline, the silencer tTS binds to PBI-1, thus
repressing background activity of this promoter. The presence of doxycycline leads to its release and binding of rtTA instead, thereby inducing gene
expression of reporter genes rfp and tk39. The plasmid components of the mifepristone-inducible HSV-Switch-TG17 vector encode the chimeric
transactivator Gal4-hPR-LBD-p65 and the PET-reporter gene HSV-1-tkgfp under the control of a synthetic promoter consisting of four GAL4 upstream
response elements and a TATA box. TG17 gene expression is induced by the chimeric transactivator protein in the presence of mifepristone. (B)
Western Blot analysis of reporter expression was performed by infecting human Gli36DEGFR cells with HSV-Switch-TG17, HSV-TG17, HET6C-tk39 or
HET6C-luc, respectively. Protein signals for the fusion protein TG17 were only obtained by infection of cells with HSV-TG17, where expression of TG17
is under control of the constitutive CMV-promoter, or HSV-Switch-TG17 in the presence of the inducer mifepristone. The doublet band visible in HSV-
TG17 infected cells may be due to sample processing with reducing agents and has already been seen and described for other TKGFP fusion
constructs as well as wt HSV-thymidine kinase. TK39-protein signal was detectable only in cells that were infected with HET6C-tk39 and treated with
doxycycline.
doi:10.1371/journal.pone.0000528.g001
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Time- and dose-dependent induction of RFP and
TKGFP expression in cell culture
To study drug dose- and time-dependent variations of induced
gene expression in cell culture, RFP expression was quantified
after infection of Gli36DEGFR cells with HET6C-tk39 in
untreated and doxycycline-treated (0.01 mg/ml–1.0 mg/ml) cells.
24, 48 and 72 h after induction fluorescence microscopy was
performed to count RFP-positive cells (RPC). The HET6C-tk39
system demonstrated a doxycycline dose- and time-dependent
increase in RFP-positive cells (RPC) (Figure 2A). Quantification
of numbers of RFP-positive cells as well as relative red fluorescence
per single cell showed a significant increase in the number of RPC
(422.16358.9 versus 1.562.1 RPC per field of view, mean6SD;
with a ratio of induction, mean6SD: 492.66214.4; P,0.001,
Mann-Whitney Rank Sum Test; Figure 2B) and relative red
fluorescence (mean6SD: 165.1666.0 versus 25.1612.1; mean
ratio of induction6SD: 6.063.2; P,0.001, Mann-Whitney Rank
Sum Test; Figure 2C) in doxycycline-treated versus untreated
cells (1 mg/ml, 48h).
The HSV-Switch-TG17 system leads to a significant increase in
a) the number of eGFP-positive cells (P,0.001, Mann-Whitney
Rank Sum Test) in the presence of mifepristone with a ratio of
induction, mean6SD of 14.068.8; and b) eGFP expression per
single cell (ratio of induction, mean6SD: 3.661.9; P,0.01) (see
supporting information: Figure S1 A–C). Both systems show
some leakiness of the construct but improvement on tightness was
especially achieved with the HET6C system, which is reflected in
an increased ratio of induction.
Imaging inducible HSV-1 amplicon vector-mediated
gene expression in vivo by PET
To investigate inducible HSV-1-tk39 gene expression in vivo by
PET, subcutaneous human Gli36DEGFR gliomas grown in nude
mice were infected with HSV-Switch-TG17 or HET6C-tk39
employing imaging-guided vector administration [6]. Animals
were treated either with or without the appropriate inducer.
[18F]FHBG-PET images were acquired 24–48 h after infection
and induction demonstrating distinct accumulation of [18F]FHBG
in both HSV-Switch-TG17 or HET6C-tk39-infected gliomas of
mifepristone or doxycycline-treated animals, respectively, as com-
pared to infected gliomas of untreated animals (Figure 3).
Quantification of microPET signals for in vivo transduced tumors
showed a 4.8-fold induction of TKGFP expression by mifepris-
tone, with significantly higher values for mifepristone-treated
animals (n = 7) versus untreated animals (n = 8) [specific accumu-
lation 0.2460.17 vs. 0.0560.08%ID/g; P,0.05, Student’s t-test].
Similar results were obtained in nude mice bearing subcutaneous
human Gli36DEGFR gliomas infected with HET6C-tk39 in the
presence (n = 7) or absence (n = 12) of doxycycline [mean ratio of
induction 4.7, specific accumulation 0.4760.35 vs. 0.106
0.08%ID/g; P,0.01, Student’s t-test].
Imaging the dynamics of regulated HSV-1 amplicon
vector-mediated gene expression in vivo by BLI
To further investigate the dynamics of regulated gene expression in
vivo, bioluminescence imaging was performed in subcutaneous and
intracranial xenografts of human Gli36DEGFR cells. To analyze
the dynamics of gene regulation within the same animals,
bioluminescence signal was determined pre- and post doxycycline
treatment. Furthermore, animals (n = 4) were subjected to on- and
off- treatment demonstrating up- and down-regulation of luc gene
expression in vivo (Figure 4A). Animals showed an increase in
Figure 2. Doxycycline-induced RFP-expression. (A) RFP-expression in
culture mediated by HET6C-tk39. Fluorescence microscopy of RFP-
expressing cells that were infected with HET6C-tk39 in the presence or
absence of doxycycline. Although expression of RFP in HET6C-tk39
infected but untreated cells is very tightly regulated, we find some
leakiness of the construct that is indicated by some single RFP-positive
cells slightly visible at 72 h past infection. (B) Counting of RFP-positive
cells (RPC) was performed+/2doxycycline (48 h post induction, 1 mg/
ml). Columns in dark grey represent the number of RPCs/f.o.v., column
in light grey represents the mean ratio of induction (number of RFP-
positive cells in presence or absence of doxycycline). Histograms
represent the calculated means+/2SD. (C) Relative intensity of red
fluorescence was recorded in single cells by means of a ROI analysis
using MPI-Tool imaging software, error bars signify the SD. ***, P,0.001
compared to non-induced cells (Mann-Whitney Rank Sum Test).
doi:10.1371/journal.pone.0000528.g002
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luciferase signal starting 3 days after onset of doxycycline treat-
ment. After withdrawal of doxycycline LUC-derived signal
decreased with a latency of 3 days to background values 7 days
after removal of the inducer (Figure 4B). All animals showed
a 11.8-197.5-fold increase in luciferase-derived signal after
doxycycline treatment in the in vivo transduced tumor.
Finally, the subsequent on-, off-, on-switching of HET6C-luc-
mediated luciferase expression was analyzed in intracranial
growing human Gli36DEGFR gliomas in nude mice (n = 5;
Figure 4C). At a basal state no signal was observed (d14). After
doxycycline treatment (2–3 days) the signal increases up to 9.9-fold
(d17; mean 5.5862.89). After withdrawal of doxycycline,
luciferase signal decreased to nearly background levels (d20).
Treatment with doxycycline again induced LUC expression up to
6.0-fold (d22; mean 4.9660.96). This demonstrates that repetitive
on- and off-switching of gene expression after in vivo transduction
of regulated genes is possible and that the dynamics of this process
can be non-invasively assessed by BLI.
Image validation
To validate in vivo images, histological sections were taken from
representative tumor samples from HET-infected tumors, and the
distribution of eGFP and RFP expression was analyzed by
fluorescence microscopy. As indicated in Figure 4D, constitutive
expression of eGFP could be observed and co-localized to the
same areas where induced RFP expression was detected.
DISCUSSION
This study demonstrates for the first time a detailed quantitative
analysis of inducible and regulated gene expression mediated by
universal HSV-1 amplicon vectors after in vivo transduction in
experimental gliomas using imaging-guided vector administration.
Multi-modal in vivo imaging is being employed for tumor
localization (MRI), assessment of viable target tissue for vector
application (FDG-/FLT-PET) and assessment of the regulated
tissue-dose of vector-mediated gene expression (FHBG-PET, BLI).
This study demonstrates the feasibility of imaging quantitatively
the dynamics of co-regulated genes after transduction in vivo.
Significant specific accumulation of [18F]-FHBG in infected and
induced tumors by microPET indicates that imaging gene
regulation may be possible even in the human application by
PET employing the same marker gene/marker substrate combi-
nation.
The HSV-1 amplicon vectors mediate regulatable proportional
co-expression of fluorescent genes (rfp, egfp) with either PET (HSV-
1-tk and tk39) or optical (firefly luciferase) imaging genes. The
essential feature of these vectors is that application of a single
vector mediates (i) the responsiveness to the exogenous inducer; (ii)
the presence of the responsive element driving inducible gene
expression; (iii) at least two inducible marker genes for analysis in
cell culture and histology using fluorescence microscopy and in vivo
using PET and optical imaging, one of which could be replaced by
any other transgene of interest. Various assays were employed to
analyze and quantify gene induction using fluorescence microsco-
py of infected cells in culture and histology, and the respective
enzymatic assays in vivo using PET and optical imaging. The range
of induction regarding the number of fluorescent positive cells
varied between factors of 14 (Gene-Switch) to 492 (Tet-On). With
respect to fluorescence intensity per single cell similar induction
ratios were observed (3.6- to 6.0-fold). The difference between
both vector systems concerning the range of induction may be
attributed to the fact that the HET-vector encodes a transcriptional
silencer and carries insulator elements which substantially reduce
the level of basal activity in cell culture. It should be pointed out
that in vivo some background activity was observed in the
radiotracer assay for both vectors (PET) which was not the case
for the bioluminescence assay. The ratio of induction as
determined in vivo by PET did not show a difference between
the vectors. As for both vectors some background activity of
[18F]FHBG accumulation was observed in vivo the rate of
induction of 4.7- and 4.8-fold did not reflect the range of
induction as determined by induced numbers of fluorescence
positive cells but by the increase of fluorescence intensity per single
cell (3.6- to 6.0-fold).
The non-invasive assessment of induced gene expression in vivo
with PET was demonstrated first by Sun et al. [31] using HeLa
Figure 3. In vivo imaging of regulated gene expression. Multimodal
imaging ([18F]FLT-, [18F]FDG- and [18F]FHBG-PET) of inducible gene
expression by PET in nude mice bearing subcutaneous human
Gli36DEGFR xenografts employing HSV-Switch-TG17 or HET6C-tk39.
Mice were randomized to mifepristone- or doxycycline-treated (each
group n= 7) and untreated (n-mif = 8; n-dox = 12) groups. Indicated
xenografts (arrowhead) were injected with HSV-Switch-TG17 and
HET6C-tk39 respectively (.26106 t.u.) 48h prior to PET-imaging,
resulting in high accumulation of [18F]FHBG in HSV-Switch-TG17 or
HET6C-tk39 infected and mifepristone- or doxycycline-treated tumors as
compared to some background activity in non-treated tumors.
doi:10.1371/journal.pone.0000528.g003
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Tet-On cells specifically engineered to express the transactivator
rtTA and stably transfected with a plasmid containing a bi-
directional doxycycline responsive promoter driving expression of
two PET-reporter genes. In our study, a single viral vector was
engineered containing all relevant information to induce and
monitor expression of the target gene in vivo, thus reflecting the
situation which might be applied in a diagnostic or therapeutic
paradigm for clinical application. The levels of TK expression as
measured as %ID/g tissue were found to be within the range of
values obtained with tumors infected with HSV-1 amplicon
vectors expressing the viral thymidine kinase under control of
a constitutive promoter [6,34].
Regarding non-invasive assessment of inducible LUC expres-
sion, we noted that by using HET6C-luc the BL images showed
a clear difference between non-induced and induced HET-
infected tumors. The quantitative range of induction did not
clearly match the one determined by PET imaging most likely due
to the semi-quantitative nature of BLI data. For pre-clinical
evaluation, this study demonstrates that optical imaging is a useful
modality to investigate the dynamics of regulated gene expression
(OFF-ON-OFF-ON) without the need for radiotracers and
irrespective of decay time. Further benefits of bioluminescence
imaging include minor costs, shorter scanning times, simultaneous
scanning of several animals, and its relatively easy use [4]. Several
types of vectors have recently been created that express optical
imaging genes, e.g., firefly or Renilla and Gaussia luciferases as
reporter genes to monitor gene expression in vivo [36–41] also by
means of gene induction [42,43]. However, it should be kept in
mind that optical imaging does not provide fully quantitative and
tomographic information which will restrict the value for clinical
application [44,45]. In contrast, PET has gained more importance
in clinically approved molecular imaging technologies, especially
in cancer imaging and treatment [46]. Furthermore, PET reporter
genes have the advantage of giving fully quantitative tomographic
information which can be directly transferred to clinical applica-
tion using new generations of high resolution PET scanners [47].
Vectors combining inducible and regulatable gene expression
systems and PET reporter genes will be of great interest for the
further development of gene therapeutic vectors and their
potential use in clinical application. By co-expressing therapeutic
genes with imaging marker genes, an indirect assessment of any
therapeutic gene is possible. Furthermore, the use of bi-directional
promoters can be used to combine expression of two independent
genes as demonstrated in this study. Recently, Dumortier et al.
2005 [43] described the use of an adenoviral vector encoding for
firefly luciferase and interferons a, b and c, respectively, co-
Figure 4. In vivo bioluminescence imaging of doxycycline-dependent gene expression over time. Bioluminescence imaging of induced LUC
expression and image validation by histology. Unit for all color scales as well as the histogram on temporal analysis was defined as photons/second/
cm2/steradian (p/s/cm2/sr). (A) Temporal analysis of up- and down-regulation of LUC expression. HET-6C injection was performed intratumorally at
day 0. Days where bioluminescent images were obtained are indicated at the upper right corner, days of doxycycline treatment at the top. (B)
Quantitative analysis of luciferase signal (OFF-ON-OFF) in response to doxycycline. (C) Temporal analysis of up- and down-regulation of LUC
expression in the intracranial glioma model (OFF-ON-OFF-ON). Indicated are the days of tumor growth. (D) Image validation by histology. BLI of
a mouse bearing a subcutaneous glioma stably expressing LUC on its left shoulder after in vivo transduction with HET6C-luc in the tumor on the right
shoulder. Representative histological sections taken from the in vivo transduced tumor showing co-localization of eGFP, expressed constitutively from
the herpes viral immediate early 4/5 promoter (Figure 1), and RFP, expressed from the bi-directional regulated promoter (Scale bar overlay: 150 mm,
exposure time: 0.5 s).
doi:10.1371/journal.pone.0000528.g004
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expressed under control of the bi-directional tet-responsive
promoter (PBI-1), thus allowing to study the effects of local cytokine
expression in a hepatitis mouse model demonstrating further the
potential of the bi-directional inducible promoter system.
In conclusion, universal HSV-1 amplicon vectors were
generated capable of transducing inducible and regulatable gene
expression in cell culture and in vivo which allow monitoring of the
quantitative dynamics of regulated gene expression by means of non-
invasive fluorescence, bioluminescence and PET imaging. These
types of vectors will be of great interest in the further development
of gene therapy for clinical application, where tight regulation of
gene expression and technology for non-invasive assessment of the
efficiency and safety of vectors is of critical importance.
MATERIALS AND METHODS
Cell culture
Human Gli36DEGFR glioma cells (Dr. David Louis, Molecular
Neurooncology Laboratory, MGH, Boston, MA) were grown as
monolayers in Dulbecco’s modified Eagle medium (DMEM; Life
Technologies, Karlsruhe, Germany) supplemented with 10% fetal
bovine serum (FBS, Roche Diagnostics, Mannheim, Germany),
1% penicillin and 1% streptomycin (P/S, Life Technologies ) at
37uC in a 5% CO2/95% air atmosphere.
HSV-1 amplicon plasmid construction and helper
virus-free packaging
Construction of the inducible double-gene co-expression vectors
was performed by PCR-amplification and standard cloning techni-
ques (see supporting information: Text S1). Helper virus-
free stocks of the HSV-1 amplicon construct pHSV-Switch-TG17
and pHET-6C-tk39 were generated as described previously [34].
Functional assessment of gene expression in culture
To assess HSV-1 amplicon vector-mediated regulation of tkgfp, rfp
and tk39 gene expression, Gli36DEGFR cells were infected with
HET6C-tk39 or HSV-Switch-TG17 in the absence or presence of
the appropriate inducer, and protein expression of HSV-1-TK,
the number of RFP- or eGFP-positive cells (RPCs or GPCs) and
the level of RFP- or eGFP-fluorescence were investigated as
described previously [34].
(i) Western Blot
To provide analysis of the induced expression of the tkgfp fusion
and the tk39 genes, human Gli36DEGFR glioma cells were
infected with HSV-Switch-TG17 and HET6C-tk39, respectively,
using a multiplicitiy of infection (MOI) of 3. Twenty-four hours
after infection cells were lysed in buffer containing 10 mM Tris
pH 8.0, 1 mM EDTA, 1 mM DTT, 0.5% Triton X-100 and
protease-inhibitor-mix (Roche Diagnostics GmbH, Mannheim,
Germany). The amount of protein present in each sample was
quantified using a BCA Protein Assay (Pierce, Rockford, IL, USA).
Equal amounts of denatured (95uC, 5 min) protein were separated
using SDS-PAGE and blotted to PVDF membrane (Amersham
Pharmacia Biotech, Freiburg, Germany) in standard Tris-glycine
transfer buffer. After blocking of non-specific binding sites with 5%
non-fat dry milk in 0.3% PBS-Tween20 (PBST) for 1 hour the
membrane was washed 3 times with PBST and incubated for
1 hour with a rabbit polyclonal anti-HSV-1-TK antibody (a kind
gift from Dr. Margeret Black, Washington State University,
Pullmann, WA) (1:20,000 in 5% dry milk in PBST). Afterwards
the membrane was washed and incubated for 1 hour with the
secondary antibody (1:20,000 in PBST; goat anti-rabbit Dianova).
Proteins were visualized using the SuperSignal West Pico
Chemiluminescence substrate (Pierce, Rockford, IL, USA).
(ii) Quantification of RFP- and eGFP-positive cells
(RPCs, GPCs)
For determination of RPCs or GPCs, human Gli36DEGFR glioma
cells were plated in 24-well plates (26105 cells per well) to form
confluent monolayers. Twenty four hours later, cells were infected
with HET6C-tk39 or HSV-Switch-TG17 at an MOI of 0.3. Two
hours after infection, the medium was replaced by medium
containing either doxycycline (dox; 0.01–1.0 mg/ml) or mifepristone
(MF; 161028–161027M) or no inducer. Representative pictures
were taken 24, 48 and 72 hr after infection. For each time point,
RPCs and GPCs, respectively, were counted in at least four fields of
view. To determine the ratio of induction, GPCs and RPCs were
counted in the presence and absence of inducer, and the ratio
(RPCs+dox/RPCs-dox or GPCs+MF/GPCs-MF) was calculated.
Animal Experiments
All animal procedures were in accordance with the German Laws
for Animal Protection and were approved by the local animal care
committee and the Bezirksregierung Ko¨ln.
(i) Tumor model and imaging-guided vector
application in vivo
To study HSV-1 amplicon vector-mediated tk gene expression in
vivo, subcutaneous Gli36DEGFR tumors, vector application and
PET imaging were performed as described previously [6,34].
Multiple sets of animals were analyzed: HET6C-tk39 (n = 19),
HSV-Switch-TG17 (n= 15) and HET6C-luc (n = 4), vector doses
ranging between 26106 to 36107 t.u. in 50 ml of PBS. Moreover,
Gli36DEGFR cells (16105 cells in 2 ml of DMEM) were
stereotactically implanted into the right striatum of nude mice
(n = 5). For application of HET6C-luc vector in pre-established i.c.
gliomas, 56105 t.u. HET6C-luc were stereotactically infused over
10 min. In the case of infection with HSV-Switch-TG17, mice
were given mifepristone intraperitoneally (500 mg/kg body weight
dissolved in sesame oil) or sesame oil as a control, whereas mice
infected with HET6C-vectors were treated with or without
doxycycline (2 mg/ml) via drinking water. To determine the rate
of induced gene expression in vivo, PET and bioluminescence
imaging was performed 24–48 hours after vector administration.
(ii) Radiosynthesis of radiotracers [18F]FDG, [18F]FLT
and [18F]FHBG was performed as described
previously [6,34]
(iii) PET
To avoid vector application into necrotic tumor, viable tumor
tissue was visualized by means of [18F]FDG- or [18F]FLT-PET
after intravenous (i.v.; tail vein) administration of no-carrier-added
[18F]FDG or [18F]FLT (no-carrier-added) into experimental
animals with doses ranging between 200–300 mCi/mouse. To
non-invasively assess the level of induced TKGFP or TK39
expression, no-carrier-added [18F]FHBG was administered i.v.
(300 mCi/mouse). To study tracer accumulation and wash out,
PET imaging was performed as described previously [6,34].
(iv) Bioluminescence imaging in vivo
Analysis of luciferase gene expression was performed on an
IVIS200 optical imaging system (Xenogen Corp., USA) at
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multiple time points after vector application (48 hours, 2–19 days).
For bioluminescence detection, mice were injected intraperitone-
ally with D-luciferin (4 mg/animal in 200 ml PBS) and images
were acquired 10 min after luciferin injection at standard camera
settings for BLI with exposure time 1–5 min. Data evaluation
based on a ROI analysis of BLI images to determine maximum
values in photons/s/cm2/sr was performed by the use of Living
Image Software version 2.50 (Xenogen Corp., USA). Data were
background subtracted and ratios of induction [photons/s/cm2/
sr+dox/photons/s/cm2/sr–dox] were determined.
(v) MRI
To allow exact co-registration of gene expression data obtained by
PET and optical imaging, T1-weighted MR images for localiza-
tion of tumors were obtained on a 1.5 T Philips Gyroscan Intera
or a 7 T Bruker Biospin animal scanner prior to in vivo
transduction.
(vi) Histology
To validate images of induced gene expression, animals were
sacrificed after imaging and tumors were processed as described
previously [6,34]. For fluorescence detection, slides were examined
by use of a fluorescence microscope (Zeiss Axiovert 135, Carl
Zeiss, Heidenheim, Germany).
Statistics
Descriptive statistics and regression analysis were performed with
Microsoft Excel 2002 (Microsoft Corp.). Student’s t-test as well as
Mann-Whitney Rank Sum Test were performed with SigmaStat
3.0 (SPSS Inc.); statistical significance was set at the less than 5%
level (P,0.05), statistical tests in SigmaStat are two-tailed.
SUPPORTING INFORMATION
Figure S1 Regulated eGFP expression in culture. (A) Fluores-
cence microscopy of eGFP-expressing cells with and without
mifepristone-treatment of HSV-Switch-TG17 infected cells. (B)
eGFP-positive cells (GPC) were counted per field of view (f.o.v.) in
the absence and presence of mifepristone (2/+MF, 24h post
induction). Columns in dark grey represent the number of GPCs/
f.o.v., whereas the column in light grey represents the mean ratio
of induction calculated as the number of GFP-positive cells with
inducer divided by the number of GFP-positive cells without
inducer, error bars signify the SD. ***, P,0.001 compared to non-
induced cells (Mann-Whitney Rank Sum Test). (C) Quantification
of relative GFP-fluorescence was determined by recording the
relative intensity of green fluorescence in single cells by means of
a region-of-interest (ROI) analysis using MPITool imaging
software, again error bars signify the SD. **, P,0.01 compared
to non-induced cells (Student’s t-test).
Found at: doi:10.1371/journal.pone.0000528.s001 (7.22 MB TIF)
Text S1
Found at: doi:10.1371/journal.pone.0000528.s002 (0.03 MB
DOC)
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